9963ISS-59074-PEMBRO-LENVOpenA phase II trial of combination therapy of pembrolizumab and Lenvatinib in patients with locally advanced or metastatic cervical cancerThis is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer. ISS# 59074; STUDY00003849NCT04865887Industrial; InstitutionalAdultTreatmentDrug: Pembrolizumab
Drug: LenvatinibIIGlobalCervixThis study investigates the following conditions or diseases: Cervical cancer, Metastatic Cervical Cancer Khleif, SamirAugusta University; Georgetown University Medical Center : Jamie Manganti; Hackensack University Medical Center; Lombardi Comprehensive Cancer Center : Jamie Manganti; University of Texas Health Science Center at HoustonGyn. Onc.Oncology GroupLombardi Comprehensive Cancer Center (LCCC)- 16801Jamie MangantiJamie Mangantijm3821@georgetown.edu
2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>